← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Curi Bio Inc
Seattle, WA
$11,985,726
Total funding
12
Grants
Funding over time
peak $2.1M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,985,726 · 12
By mechanism
R44$8,283,791 · 4
U44$2,086,960 · 1
R43$1,614,975 · 7
Investigators at Curi Bio Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A cross-species preclinical platform to enhance the translation of new medicines$1,149,771
R44 · FY2025 · TR
High-Throughput NMJ Assay for Botox Potency Screening$910,019
U44 · FY2024 · TR
High-Throughput NMJ Assay for Botox Potency Screening$901,175
U44 · FY2025 · TR
A cross-species preclinical platform to enhance the translation of new medicines$832,365
R44 · FY2024 · TR
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$750,000
R44 · FY2022 · HL
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$750,000
R44 · FY2020 · HL
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$750,000
R44 · FY2021 · HL
High-throughput nanoMEA-based Proarrhythmia Assay$748,435
R44 · FY2018 · HL
High-throughput nanoMEA-based Proarrhythmia Assay$747,868
R44 · FY2019 · HL
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$745,488
R44 · FY2021 · HL
A cross-species preclinical platform to enhance the translation of new medicines$324,648
R44 · FY2023 · TR
High-Throughput NMJ Assay for Botox Potency Screening$275,766
U44 · FY2023 · TR
Cryopreserving Stem Cell-Derived Cardiomyocytes in Ready-to-use Assay Plates for Improved Reproducibility of Drug Toxicity Testing$252,131
R43 · FY2020 · HL
Maturation of stem cell-derived cardiomyocytes using a simulated microgravity bioreactor and combinations of extracellular developmental cues$252,131
R43 · FY2020 · HL
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$242,088
R44 · FY2022 · HL
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$225,000
R44 · FY2019 · HL
A Nanopatterned Interdigitated Electrode Array Device for Anti-migratory Cancer Drug Screening$225,000
R43 · FY2017 · CA
A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells$225,000
R43 · FY2019 · HL
Multiplexed quantitative measurements of field potential and contractility on biomimetically-matured hPSC-CMs$225,000
R43 · FY2019 · EB
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$225,000
R44 · FY2020 · HL